News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Pulmovant (Roivant) will present topline Phase 2 PHocus results for mosliciguat in PH-ILD at the ERS Congress on Sept 8.
  • Roivant will host an investor call immediately after the ERS presentation to discuss the topline findings.
  • Topline results will affect Pulmovant and respiratory-biotech sector valuations.
  • Star Group offers a yield above 6% and has raised distributions for 14 consecutive years.
  • Star Group generates roughly $56.8M in free cash flow with an enterprise value below $600M.
  • SGU trades at about a 5.2 P/E and ~3.2 EV/EBITDA, framing it as a reversion/value trade for income investors.

Latest Articles

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma to Present at September Investor Conferences

Crescent Biopharma, a clinical-stage biotech company focusing on innovative cancer therapies, announced its management will present at the 2026 Cantor Global Healthcare Conference and Morgan Stanley Global Healthcare Conference in September. The presentations will highlight the company's pipeline developments including a PD-1 x VEGF bispecific anti…

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis

The FDA has granted Fast Track designation to Liquidia Corporation's inhaled powder drug YUTREPIA (treprostinil) for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP), a condition with significant unmet medical need and no approved therapies in the United States. This designation will help expedite the development an…

Hillman Completes Acquisition of Kanebridge

Hillman Completes Acquisition of Kanebridge

Hillman Solutions Corp., a leading hardware product provider, has completed its acquisition of Kanebridge, LLC, a master distributor of industrial fasteners, for approximately $315 million. This strategic move significantly expands Hillman's industrial addressable market to around $3 billion and establishes its first U.S. master distribution platfo…

Amwell® receives Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for addressing healthcare fragmentation

Amwell® receives Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for addressing healthcare fragmentation

Amwell received Frost & Sullivan's 2026 Technology Innovation Leadership Recognition for its unified technology platform that addresses healthcare fragmentation by integrating consumer experiences, clinician workflows, care programs, and partner solutions. The award highlights Amwell’s innovation and business impact in creating a connected infrastr…

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

Alterity Therapeutics, a biotechnology company focused on neurodegenerative diseases, announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026. The company is preparing for a Phase 3 pivotal trial for its lead drug ATH434, which has shown promising results in Phase 2 trials for Multiple Sy…

Polestar Trims Annual Delivery Target After U.S. Sales Ban Forces Exit

Polestar Trims Annual Delivery Target After U.S. Sales Ban Forces Exit

Polestar said on Sept. 3 that it has lowered its full-year delivery forecast after U.S. authorities barred the China-linked automaker from selling vehicles in the United States from model year 2027 onwards. The decision comes as the company reported weaker revenue, narrowed losses versus a year earlier, significant restructuring charges tied to its…

Azimut Shares Jump After Deutsche Bank Upgrade and Strong H1 Results

Azimut Shares Jump After Deutsche Bank Upgrade and Strong H1 Results

Azimut Holding SpA rose 3.6% to €39.26 after Deutsche Bank upgraded the stock to 'buy' and lifted its 12-month price target to €46 from €35. The upgrade cited strong first-half 2026 results, including double-digit recurring revenue and recurring net profit growth and record assets under management, along with a new share buyback and a capital retur…

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference

BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on innovative small molecule cancer treatments, will present at the 8th Annual RAS-Targeted Drug Development Summit and the H.C. Wainwright 28th Annual Global Investment Conference. The company highlighted its leading programs including BH-30643, a Fast Track designated dr…

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference

Fate Therapeutics announced management's participation in a fireside chat at the upcoming 2026 Annual Cantor Global Healthcare Conference to discuss its iPSC-derived off-the-shelf CAR T-cell product candidate FT819, recent clinical progress including the start of the Phase 2 RECLAIM-LN trial for lupus nephritis, and the unique safety profile of FT8…

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

Eledon Pharmaceuticals announced multiple milestones for its lead drug candidate tegoprubart, including IND submission to FDA for an islet cell transplantation trial, enrollment of first patients in investigator-initiated studies, compassionate use dosing in transplant patients with renal dysfunction and high sensitization, and reaffirmed plans to …

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics announced it will present new biomarker data demonstrating the immunomodulatory effects of its investigational drug cemsidomide, combined with dexamethasone, from its Phase 1 relapsed/refractory multiple myeloma trial at the 23rd International Myeloma Society Annual Meeting. The data highlights the drug's impact on T and NK cells, s…

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

LeonaBio to Participate in Cantor Global Healthcare Conference 2026

LeonaBio, a clinical-stage biopharmaceutical company listed on NASDAQ, announced its participation in the Cantor Global Healthcare Conference 2026. Management will engage in a fireside chat to discuss their novel therapeutic developments targeting diseases with high unmet medical needs, including metastatic breast cancer and ALS. The event will fea…

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

Climb Bio announced positive Phase 1 trial data for its anti-APRIL monoclonal antibody, CLYM116, showing a ~29-day half-life and sustained APRIL suppression with favorable safety. The data supports an every-12-week dosing regimen for treating IgA nephropathy. The Phase 2 NAVIGATE-2 trial is ongoing with initial data expected in H1 2027, and a Phase…

Victoria’s Secret & Co. Reports Second Quarter 2026 Results

Victoria’s Secret & Co. Reports Second Quarter 2026 Results

Victoria's Secret & Co. reported a strong second quarter in 2026 with net sales increasing 10% to $1.611 billion, operating income rising to $257 million, and adjusted operating income surpassing guidance at $124 million. The company has raised its full-year 2026 net sales and adjusted operating income guidance, citing growth across all business se…

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Avalo Therapeutics announced its participation in several upcoming investor conferences, including the Cantor Global Healthcare Conference and Morgan Stanley Annual Global Healthcare Conference. The company focuses on developing IL-1β pathway therapeutics for immune-mediated inflammatory diseases and is advancing its lead candidate, abdakibart, int…